Search company, investor...
Timber Pharmaceuticals company logo

Timber Pharmaceuticals



Total Raised


Date of IPO


About Timber Pharmaceuticals

Timber Pharmaceuticals (NYSEAMERICAN: TMBR) provides drug-delivery products through its unique platform technologies for pharmaceutical and OTC applications. BioPharmX products address unmet needs in large, well-defined, and under-served markets; including dermatology, women's health, and ear, nose and throat (ENT) therapy.

Headquarters Location

1505 Adams Drive Suite D

Menlo Park, California, 94025,

United States


Missing: Timber Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Timber Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Timber Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Timber Pharmaceuticals is included in 2 Expert Collections, including Women's Health & Wellness.


Women's Health & Wellness

1,487 items

Startups focused on providing products and services catering to women's health and wellbeing.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Timber Pharmaceuticals Patents

Timber Pharmaceuticals has filed 20 patents.

The 3 most popular patent topics include:

  • Dosage forms
  • Drug delivery devices
  • NMDA receptor antagonists
patents chart

Application Date

Grant Date


Related Topics




Dosage forms, Genodermatoses, Drug delivery devices, Rare diseases, Cutaneous conditions


Application Date


Grant Date



Related Topics

Dosage forms, Genodermatoses, Drug delivery devices, Rare diseases, Cutaneous conditions



Latest Timber Pharmaceuticals News

Timber Pharmaceuticals to Host Investor Business Briefing: Milestone Achievements and Forward Outlook

Dec 14, 2022

Virtual Business Briefing With Q&A to be Webcast on December 20, 2022 at 10:30 am ET BASKING RIDGE, NJ, Dec. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced it will host a virtual investor Business Briefing with Q&A on December 20, 2022, at 10:30 am ET. John Koconis, Chairman and Chief Executive Officer of Timber, will discuss the Company’s milestone achievements in 2022, as well as what investors can expect to see in 2023 and beyond. Mr. Koconis said, “We believe Timber has achieved a number of important milestones in 2022, including TMB-001 receiving FDA Fast Track and Breakthrough Therapy designations, which are designed to expedite the development and review of drugs that treat serious conditions and meet unmet medical needs. TMB-001 (IPEG™ topical isotretinoin) is our lead product and is being developed for the treatment of moderate to severe subtypes of congenital ichthyosis. Congenital ichthyosis (CI) is a rare and serious inherited skin disorder characterized by dry, scaling skin that often is abnormally thick. “Additionally, Timber received official orphan designation for TMB-001 for the treatment of autosomal recessive congenital ichthyosis (ARCI) from the European Commission, which will provide 10 years of market exclusivity for TMB-001 in the European Union once we receive European product approval. “TMB-001 is now in late-stage development, with recruitment for our pivotal Phase 3 ASCEND clinical trial progressing to plan. We have begun exploring partnerships and licensing agreements for TMB-001 and we are in ongoing discussions with potential candidates throughout Europe. We look forward to connecting with investors at Timber’s Business Briefing later this month.” Timber was recently featured on CheckRare, a learning platform dedicated to providing clinical updates and practical information about rare and orphan diseases. Watch here as Alan Mendelsohn, MD, Timber’s Chief Medical Officer, discusses TMB-001’s mechanism of action. The live and archived webcast of the Company’s Business Briefing will be available at . About Timber Pharmaceuticals, Inc. Timber Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases. The Company's investigational therapies have proven mechanisms-of-action backed by decades of clinical experience and well-established CMC (chemistry, manufacturing and control) and safety profiles. The Company is initially focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis (CI) and other sclerotic skin diseases. For more information, visit and follow us on LinkedIn and Twitter at @TimberPharma . Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, intellectual property rights, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential, "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2021 as well as other documents filed by the Company from time to time thereafter with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. For more information, contact:

Timber Pharmaceuticals Frequently Asked Questions (FAQ)

  • Where is Timber Pharmaceuticals's headquarters?

    Timber Pharmaceuticals's headquarters is located at 1505 Adams Drive, Menlo Park.

  • What is Timber Pharmaceuticals's latest funding round?

    Timber Pharmaceuticals's latest funding round is IPO.

  • How much did Timber Pharmaceuticals raise?

    Timber Pharmaceuticals raised a total of $500K.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.